Xoma Corp., of Emeryville, Calif., said it licensed the global development and commercialization rights for XOMA-358, a fully human antibody that inhibits the effects of elevated insulin (hyperinsulinemia) via allosteric modulation of the insulin receptor, to Rezolute Inc. (formerly Antriabio Inc.), of Louisville, Colo., and in return Xoma will be entitled to receive up to approximately $240 million.